Acadia announced that the Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted in favor (12-2) that the benefits of Nuplazid (primavanserin) outweighed the risks for the treatment of psychosis associated with Parkinson's' disease.

Declines in cognition could have a greater impact on the ability of Parkinson's disease patients to converse than physical impairment, according to research published online in the Journal of Parkinson's Disease.